Logo

Interpace Biosciences: Thomas Burnell, Jack Stover

Nov 25, 2020

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.